Literature DB >> 26382310

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.

.   

Abstract

OBJECTIVE: To update and expand The North American Menopause Society's evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS.
METHODS: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees.
RESULTS: Nonhormonal management of VMS is an important consideration when hormone therapy is not an option, either because of medical contraindications or a woman's personal choice. Nonhormonal therapies include lifestyle changes, mind-body techniques, dietary management and supplements, prescription therapies, and others. The costs, time, and effort involved as well as adverse effects, lack of long-term studies, and potential interactions with medications all need to be carefully weighed against potential effectiveness during decision making.
CONCLUSIONS: Clinicians need to be well informed about the level of evidence available for the wide array of nonhormonal management options currently available to midlife women to help prevent underuse of effective therapies or use of inappropriate or ineffective therapies. Recommended: Cognitive-behavioral therapy and, to a lesser extent, clinical hypnosis have been shown to be effective in reducing VMS. Paroxetine salt is the only nonhormonal medication approved by the US Food and Drug Administration for the management of VMS, although other selective serotonin reuptake/norepinephrine reuptake inhibitors, gabapentinoids, and clonidine show evidence of efficacy. Recommend with caution: Some therapies that may be beneficial for alleviating VMS are weight loss, mindfulness-based stress reduction, the S-equol derivatives of soy isoflavones, and stellate ganglion block, but additional studies of these therapies are warranted. Do not recommend at this time: There are negative, insufficient, or inconclusive data suggesting the following should not be recommended as proven therapies for managing VMS: cooling techniques, avoidance of triggers, exercise, yoga, paced respiration, relaxation, over-the-counter supplements and herbal therapies, acupuncture, calibration of neural oscillations, and chiropractic interventions. Incorporating the available evidence into clinical practice will help ensure that women receive evidence-based recommendations along with appropriate cautions for appropriate and timely management of VMS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26382310     DOI: 10.1097/GME.0000000000000546

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  55 in total

1.  Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study.

Authors:  Debra L Barton; Kelliann C Fee Schroeder; Tanima Banerjee; Sherry Wolf; Timothy Z Keith; Gary Elkins
Journal:  Menopause       Date:  2017-07       Impact factor: 2.953

2.  An efficient tool for the primary care management of menopause.

Authors:  Susan Goldstein
Journal:  Can Fam Physician       Date:  2017-04       Impact factor: 3.275

3.  Management of Potential Long-Term Toxicities in Breast Cancer Patients.

Authors:  C C O'Sullivan; K J Ruddy
Journal:  Curr Breast Cancer Rep       Date:  2016-10-13

4.  Comparative efficacy of nonhormonal drugs on menopausal hot flashes.

Authors:  Lujin Li; Ling Xu; Junyi Wu; Lidan Dong; Shuiyu Zhao; Qingshan Zheng
Journal:  Eur J Clin Pharmacol       Date:  2016-07-24       Impact factor: 2.953

5.  Vasomotor symptom characteristics: are they risk factors for incident diabetes?

Authors:  Kristen E Gray; Jodie G Katon; Erin S LeBlanc; Nancy F Woods; Lori A Bastian; Gayle E Reiber; Julie C Weitlauf; Karin M Nelson; Andrea Z LaCroix
Journal:  Menopause       Date:  2018-05       Impact factor: 2.953

Review 6.  Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis.

Authors:  M Shepherd-Banigan; K M Goldstein; R R Coeytaux; J R McDuffie; A P Goode; A S Kosinski; M G Van Noord; D Befus; S Adam; V Masilamani; A Nagi; J W Williams
Journal:  Complement Ther Med       Date:  2017-08-24       Impact factor: 2.446

7.  Topical, geospatial, and temporal diffusion of the 2015 North American Menopause Society position statement on nonhormonal management of vasomotor symptoms.

Authors:  Janet S Carpenter; Tei Laine; Blake Harrison; Meghan LePage; Taran Pierce; Nathan Hoteling; Katy Börner
Journal:  Menopause       Date:  2017-10       Impact factor: 2.953

8.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

9.  The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview.

Authors:  Cheryl Phua; Rodney Baber
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

10.  Stellate ganglion blockade and verbal memory in midlife women: Evidence from a randomized trial.

Authors:  Pauline M Maki; Leah H Rubin; Antonia Savarese; Lauren Drogos; Lee P Shulman; Suzanne Banuvar; David R Walega
Journal:  Maturitas       Date:  2016-07-17       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.